PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “GASTROINTESTINAL MOTILITY”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources

Functional significance of a newly discovered neuropeptide, orphanin FQ, in rat gastrointestinal motility.

BACKGROUND & AIMS: Orphanin FQ (OFQ) is a recently discovered neuropeptide that structurally resembles an opioid peptide. However, the functional role of OFQ in rat gastrointestinal tract remains unknown. METHODS: We investigated the effects of OFQ on contractions of muscle strips obtained from different regions of the gastrointestinal tract. Immunohistochemical studies were performed on rat colonic tissue using OFQ antibody. RESULTS: OFQ (10(-9) to 10(-7) mol/L) caused significant contractions in the rat colon but not in the stomach or small intestine. Tetrodotoxin, veratridine, and long-term serosal application of benzalkonium chloride completely abolished OFQ-induced colonic contractions without affecting myogenic contractions in response to carbachol. OFQ-induced contractions were not affected by naloxone, atropine, phentolamine, propranolol, methysergide, substance P antagonist, vasoactive intestinal polypeptide antagonist, apamin, and NG-nitro-L-arginine methyl ester. OFQ (10(-9) to 10(-7) mol/L) significantly reduced muscle contractions and 3H-acetylcholine release in response to electrical field stimulation in both the stomach and small intestine but not in the colon. OFQ-immunopositive neuronal fibers were found in the colonic myenteric plexus. CONCLUSIONS: These studies indicate that the mechanisms and sites of action of OFQ are region specific. OFQ inhibits cholinergic transmission in the stomach and small intestine, whereas OFQ stimulates colonic contraction possibly by inhibiting an inhibitory neural pathway within the myenteric plexus.

Acetylcholine↗

[Effect of kappa-casein glycomacropeptide on gastrointestinal motility in dogs].

Glycomacropeptide, which provoked a significant inhibition of food motility of the stomach fundus on intravenous injection to dogs in a dose of 10 mg, was isolated from the products of restricted pepsin proteolysis of cow kappa-casein with the aid of gel chromatography on Sephadex G-25 and G-10. Glycomacropeptide administered on an empty stomach produced cyclic-repetitive vomiting. Physiological action of glycomacropeptide (inhibition of gastric secretion and motility) may play an important role in the preservation of biologically active milk proteins and peptides in the gastrointestinal tract of the newborn.

Animals↗

Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders.

Ghrelin was first discovered as a peptide involved in growth hormone release, but has now emerged as a new player in the regulation of gastrointestinal function. Ghrelin is structurally and functionally related to motilin. Like motilin, it induces a specific motor pattern in the fasted state and acts postprandially to accelerate gastric emptying. There is no apparent cross-reactivity with motilin at the receptor level. Ghrelin agonists have the same potential as motilin agonists, and applications in post-operative ileus and gastroparesis have already been explored. Although promising, there is still the need to avoid side effects and the problems encountered with motilides. This will require drugs with an appropriate pharmacokinetic profile. In addition, the dosage regimen and target population should be carefully taken into consideration when planning clinical trials.

Gastrointestinal Agents↗

Prostaglandin E2: a neuromodulator in the central control of gastrointestinal motility and feeding behavior by calcitonin.

Two micrograms of prostaglandin E2 injected into the lateral ventricle of the brain in rats had the same anorectic and gastrointestinal motor effect as central administration of 0.02 unit of calcitonin. The effects of calcitonin were blocked by a previous intracerebroventricular administration of 0.25 milligram of indomethacin. These results suggest that both anorectic and gastrointestinal motor effects of calcitonin are centrally mediated by the release of prostaglandins.

Animals↗

Gastrointestinal motility and glycemic control in diabetes: the chicken and the egg revisited?

Upper gastrointestinal dysfunction occurs frequently in diabetes and potentially contributes to both abdominal symptoms and impaired glycemic control; conversely, variations in blood glucose concentration reversibly affect gut motility in humans. In this issue of the JCI, Anitha et al. report apoptosis of rodent enteric neurons under hyperglycemic conditions, both in vitro and in vivo, associated with impaired PI3K activity and preventable by glial cell line-derived neurotrophic factor. These observations add to recent insights gained from animal models regarding the etiology of diabetic gastrointestinal dysfunction, but investigators must strive to translate animal data to human diabetes.

Animals↗